Raising Venture Capital for a Nanoparticle Therapeutics Company
Volume 5, Issue 2
Mark J. Graffagnini, Wilson Sonsini Goodrich & Rosati, P.C.
Several notable venture capital investments have been made in the last twelve months in early stage
companies developing nanoparticle therapeutics. Examples include BIND Biosciences, Ensysce
Biosciences, Carigent Therapeutics, NanoMed Pharmaceuticals, and Tempo Pharmaceuticals. In this
article, corporate attorney Mark J. Graffagnini explains why nanoparticle therapeutic companies
generally require considerable venture capital financing, surveys recent deals, and discusses how venture
investors are likely to assess the value of such companies. He also describes typical conditions of
investment in these types of early stage companies, including board control, operating conditions, and
preferred stock rights.
Full Text (PDF)